Session Item

This retrospective study evaluated at the tolerability and outcomes of preoperative radiotherapy (P-RT) with concurrent chemotherapy (CT) for patients with advanced soft tissue sarcomas (ASTS). 

Between January/2016 and June/2021, 45 patients (male/female 33/12) with ASTS, were treated with P-RT (50Gy in 25 Fractions) with concurrent CT (3 cycles): Epirubicin + ifosfamide; Antitumor activity was assessed by preoperative-RMN by RECIST, modified Choi criteria and pathological response. Surgical specimens were processed for histologic changes and rate of residual visible tumor. 

The median age of 55 years (range 19-86). In term of histology, 26,6% were GII and 73,3% GIII. Patients were treated in 3D/IMRT 8/37. GTV: defined MRI; CTV: GTV +2,5cm. Patients received 50 Gy in 25 fractions at 5/week, with 3 cycles of Epirubicin 60mg/m2/d d1-2 + Ifosfamide 3g/m2/d d1-3 each 3 weeks. 66,6% patients had no acute Radiodermitis G>3. No dose-reductions or interruptions (>2 days) were registered. All patients completed RT, and 32 were evaluated for response. By RECIST: 11 achieved PR (34,3%), 15 SD (46,8%), 6 PD (18,7%). By Choi: 19 achieved PR (59,3%), 10 SD (31,2%), 3 PD (9,3%).

Median time from the end radiotherapy to surgery was 33 days (range, 11-74 days).

Median pathological response was 87% (range 15-100%). With a median follow-up of 30 months (4 - 51 months), there were 10 progression and 4 death events

RT-CT preoperative have shown relevant clinical activity in ASTS, favorable safety profile and antitumor activity in the preoperative setting of patients affected by ASTS